Streetbeat News

Revenues

CHRD

Chord Energy Inc. (NASDAQ:CHRD) has seen a 1.15% decrease in its share price to $136.19. Despite a 0.96% increase over the past month, the stock has decreased by 18.22% over the past year. The company's P/E ratio is lower than the industry average, suggesting potential undervaluation or weak growth prospects.

Portfolio Pulse from Benzinga Insights

October 08, 2024 | 4:15 pm

RCAT

Red Cat shares rose following the announcement of a $1.6 million contract for Edge 130 Blue Drones.

Portfolio Pulse from Benzinga Newsdesk

October 08, 2024 | 4:11 pm

TPC

Tutor Perini has secured a $1.66 billion contract for the City Center Guideway and Stations Project in Honolulu, involving the design and construction of six rail stations and three miles of elevated rail guideway. Project design starts immediately, with construction beginning in the second half of 2025 and completion expected by 2030.

Portfolio Pulse from Benzinga Newsdesk

October 08, 2024 | 4:09 pm

PSX

Analysts have provided a range of ratings for Phillips 66 (NYSE:PSX) over the past three months, with a mix of bullish and somewhat bullish sentiments. The average 12-month price target has decreased by 2.3% to $151.92. Recent analyst actions include both raises and lowers in ratings and price targets, reflecting changing market conditions and company performance. Phillips 66 has shown solid revenue growth and strong profitability metrics, with a conservative debt management approach.

Portfolio Pulse from Benzinga Insights

October 08, 2024 | 4:01 pm

MRVI

Maravai LifeSciences (NASDAQ:MRVI) has received mixed analyst ratings over the past three months, with a slight increase in the average 12-month price target. Analysts have varied in their ratings, with some lowering and others raising their price targets. The company has shown positive revenue growth and strong financial metrics, but faces challenges with a high debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

October 08, 2024 | 4:01 pm

HUBS

HubSpot (NYSE:HUBS) has received mixed analyst ratings over the past three months, with a recent decrease in the average price target by 7.69%. Despite positive revenue growth, HubSpot faces challenges with profitability and returns on equity and assets. Analysts have adjusted their ratings and price targets in response to these dynamics.

Portfolio Pulse from Benzinga Insights

October 08, 2024 | 4:00 pm

SPRY

ARS Pharmaceuticals (NASDAQ:SPRY) has received mixed analyst ratings over the past three months, with a majority being somewhat bullish. The average 12-month price target has increased to $26.43. The company has shown significant revenue growth but struggles with profitability.

Portfolio Pulse from Benzinga Insights

October 08, 2024 | 4:00 pm

DXCM

DexCom (NASDAQ:DXCM) has significantly outperformed the market over the past 15 years, with an annualized return of 26.92%. A $100 investment in DXCM 15 years ago would be worth $3,619.92 today, highlighting the power of compounded returns.

Portfolio Pulse from Benzinga Insights

October 08, 2024 | 4:00 pm

ARMK

Analysts have provided mixed ratings for Aramark (NYSE:ARMK), with a recent positive shift in price targets. The average 12-month price target increased by 9.48% to $39.85. Analysts have raised their ratings, reflecting a more optimistic outlook. Despite this, Aramark's financial performance shows challenges, with below-average net margin, ROE, and ROA compared to industry peers.

Portfolio Pulse from Benzinga Insights

October 08, 2024 | 4:00 pm

MSOS

Dan Roda from Safe Harbor Financial notes that 2023 marks the first year with fewer active cannabis business licenses by year-end compared to the start. This is due to fewer new states launching cannabis programs, indicating market maturation and economic impacts.

Portfolio Pulse from Benzinga Newsdesk

October 08, 2024 | 3:49 pm